CTVA Stock Analysis: Corteva | NYSE
Agricultural Inputs | NYSE, USA | Market Cap: 57.565m USD | 12M Return: 20% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 328M
EPS Trend: -30.7%
Qual. Beats: 0
Rev. Trend: 27.0%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 7.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Corteva, Inc. (NYSE: CTVA) is a U.S.-based agricultural inputs company that operates through two segments: Seed and Crop Protection. The Seed segment supplies advanced germplasm and traits designed to improve yield, along with digital decision-support tools for farmers. The Crop Protection segment provides herbicides, insecticides, nitrogen stabilizers, and pasture and range management products that protect and enhance crop health. Corteva sells to the global agricultural input industry across the United States, Canada, Latin America, Asia Pacific, Europe, the Middle East, and Africa, and is headquartered in Indianapolis, Indiana.
Corteva was spun off from DowDuPont and began trading on the NYSE in May 2019, which is why the company carries an 1802 founding date tied to its predecessor heritage while its standalone public history is more recent. The Seeds and Crop Protection market is a concentrated industry dominated by a handful of large multinational players, and Cortevas vertically integrated model combines germplasm development, trait licensing, and crop chemistry with R&D-heavy product cycles typical of the agricultural inputs sector.
- Latin America planting season drives Seed volume and pricing
- Crop Protection margins face generic competition pressure
- Capital return program expands through accelerated share buybacks
| Net Income: 1.16b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -0.20 > 1.0 |
| NWC/Revenue: 30.92% < 20% (prev 30.33%; Δ 0.59% < -1%) |
| CFO/TA 0.06 > 3% & CFO 2.62b > Net Income 1.16b |
| Net Debt (1.21b) to EBITDA (3.15b): 0.39 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (673.6m) vs 12m ago -1.89% < -2% |
| Gross Margin: 46.81% > 18% (prev 44.63%; Δ 2.18% > 0.5%) |
| Asset Turnover: 42.17% > 50% (prev 39.96%; Δ 2.21% > 0%) |
| Interest Coverage Ratio: 10.79 > 6 (EBIT TTM 1.94b / Interest Expense TTM 180.0m) |
| A: 0.13 (Total Current Assets 17.4b - Total Current Liabilities 11.9b) / Total Assets 42.7b |
| B: 0.01 (Retained Earnings 436.0m / Total Assets 42.7b) |
| C: 0.05 (EBIT TTM 1.94b / Avg Total Assets 42.4b) |
| D: 1.35 (Book Value of Equity 24.4b / Total Liabilities 18.1b) |
| Altman-Z'' = 2.60 = A |
| DSRI: 1.03 (Receivables 9.12b/8.29b, Revenue 17.9b/16.8b) |
| GMI: 0.95 (GM 44.63% / 46.81%) |
| AQI: 0.97 (AQ_t 0.50 / AQ_t-1 0.51) |
| SGI: 1.06 (Revenue 17.9b / 16.8b) |
| TATA: -0.03 (NI 1.16b - CFO 2.62b) / TA 42.7b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of July 21, 2026, the stock is trading at USD 86.78 with a total of 2,794,765 shares traded. Over the past week, the price has changed by +0.82%, over one month by +10.04%, over three months by +8.33% and over the past year by +20.03%.
Current recommended Stop Loss: 81.60 (which is 6% or 2.5 ATR below the current price).
Corteva has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy CTVA.
- StrongBuy: 13
- Buy: 5
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 90.2 | 3.9% |
P/E Trailing = 46.5243
P/E Forward = 24.4499
P/S = 3.2179
P/B = 2.3522
P/EG = 1.4422
Revenue TTM = 17.9b USD
EBIT TTM = 1.94b USD
EBITDA TTM = 3.15b USD
Long Term Debt = 1.68b USD (from longTermDebt, last quarter)
Short Term Debt = 1.67b USD (from shortTermDebt, last quarter)
Debt = 3.36b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.21b USD (calculated: Debt 3.36b - CCE 2.14b)
Enterprise Value = 58.8b USD (57.6b + Debt 3.36b - CCE 2.14b)
Interest Coverage Ratio = 10.79 (Ebit TTM 1.94b / Interest Expense TTM 180.0m)
EV/FCF = 28.73x (Enterprise Value 58.8b / FCF TTM 2.05b)
FCF Yield = 3.48% (FCF TTM 2.05b / Enterprise Value 58.8b)
FCF Margin = 11.44% (FCF TTM 2.05b / Revenue TTM 17.9b)
Net Margin = 6.50% (Net Income TTM 1.16b / Revenue TTM 17.9b)
Gross Margin = 46.81% ((Revenue TTM 17.9b - Cost of Revenue TTM 9.52b) / Revenue TTM)
Gross Margin QoQ = 48.50% (prev 38.29%)
Tobins Q-Ratio = 1.38 (Enterprise Value 58.8b / Total Assets 42.7b)
Interest Expense / Debt = 5.36% (Interest Expense 180.0m / Debt 3.36b)
Taxrate = 28.38% (500.0m / 1.76b)
NOPAT = 1.39b (EBIT 1.94b * (1 - 28.38%))
Current Ratio = 1.47 (Total Current Assets 17.4b / Total Current Liabilities 11.9b)
Debt / Equity = 0.14 (Debt 3.36b / totalStockholderEquity, last quarter 24.4b)
Debt / EBITDA = 0.39 (Net Debt 1.21b / EBITDA 3.15b)
Debt / FCF = 0.59 (Net Debt 1.21b / FCF TTM 2.05b)
Total Stockholder Equity = 24.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.74% (Net Income 1.16b / Total Assets 42.7b)
RoE = 4.67% (Net Income TTM 1.16b / Total Stockholder Equity 24.9b)
RoCE = 7.30% (EBIT 1.94b / Capital Employed (Equity 24.9b + L.T.Debt 1.68b))
RoIC = 4.40% (NOPAT 1.39b / Invested Capital 31.6b)
WACC = 8.09% (E(57.6b)/V(60.9b) * Re(8.34%) + D(3.36b)/V(60.9b) * Rd(5.36%) * (1-Tc(0.28)))
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.84 | Cagr: -1.94%
[DCF] Terminal Value 75.07% ; FCFF base≈2.07b ; Y1≈2.03b ; Y5≈2.06b
[DCF] Fair Price = 46.24 (EV 32.1b - Net Debt 1.21b = Equity 30.9b / Shares 668.8m; r=8.35% [WACC [floored]]; 5y FCF grow -2.66% → 2.50% )
EPS Correlation: -30.73 | EPS CAGR: -4.83% | SUE: 0.78 | # QB: 0
Revenue Correlation: 26.99 | Revenue CAGR: 0.64% | SUE: 1.34 | # QB: 1
EPS current Quarter (2026-06-30): EPS=2.22 | Chg30d=-0.37% | Revisions=-50% | Analysts=15
EPS next Quarter (2026-09-30): EPS=-0.28 | Chg30d=-0.11% | Revisions=+0% | Analysts=15
EPS current Year (2026-12-31): EPS=3.75 | Chg30d=+0.27% | Revisions=+17% | GrowthEPS=+12.2% | GrowthRev=+5.3%
EPS next Year (2027-12-31): EPS=3.43 | Chg30d=+6.71% | Revisions=+0% | GrowthEPS=+24.7% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: -13% (up=5, down=7)